Why the study?
Does a recombinant HIV-1 Tat37-72 peptide-based multiple T cell epitope vaccine protect against auto-immune nervous system inflammation in a Lewis rat model of GANS?
Does a recombinant HIV-1 Tat37-72 peptide-based multiple T cell epitope vaccine protect against auto-immune nervous system inflammation in a Lewis rat model of GANS?
A novel recombinant HIV-1 Tat37-72 peptide-based vaccine protects against multi-compartment auto-immune nervous system inflammation in a newly established rat model.
Answers are grounded in this paper and cite their sources.
Route-dependent protection in rat autoimmune model is hypothesis-generating; human translation requires clinical trials.
A new model of multi-compartment auto-immune disease has been established to analyze the effects of polyvalent recombinant peptide vaccines. A synthetic gene encoding major pathogenic determinants for Lewis rats of guinea pig myelin basic protein (MBP68-84), bovine interphotoreceptor retinoid binding protein (IRBP1169-1191), and bovine P2 protein (P2,53-78) was used to induce Generalized Autoimmunity of the Nervous System (GANS), which is characterized by development of auto-immune infiltration of the brain and spinal cord, the eyes, the pineal organ and the peripheral nerves. Thus, this model integrates the prominent features of three auto-immune diseases: experimental autoimmune encephalomyelitis (EAE), neuritis (EAN) and uveitis (EAU). In this study, GANS was used to study the effect of HIV-1 Tat37-72 targeting peptide on vaccination by recombinant polyvalent T cell auto-antigen vaccine. Depending on the route of administration, the recombinant vaccine effectively protects against the development of auto-immune nervous system inflammation.
No takes yet. Share an insight, caveat, or question.
Hermann J. Schluesener (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: